Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRIELLYN vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) that inhibits gonadotropin secretion, primarily suppressing ovulation and altering cervical mucus and endometrial lining.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females aged ≥15 years who have achieved menarche and are not pregnant,Treatment of heavy menstrual bleeding in women without organic pathology who choose oral contraception
Prevention of pregnancy
BRIELLYN (ethinyl estradiol / norethindrone) 1 tablet (0.035 mg ethinyl estradiol / 0.5 mg norethindrone) orally once daily at the same time each day.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
12-19 hours; clinical context: steady state reached in 3-5 days, dosing adjustment recommended in renal impairment
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Ethinyl estradiol is metabolized via CYP3A4; norethindrone is metabolized primarily via reduction and conjugation, with CYP3A4 involvement.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Approximately 60% renal excretion of metabolites, 40% fecal/biliary elimination
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
97-99% bound primarily to albumin and alpha-1-acid glycoprotein
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
4-6 L/kg; extensive tissue distribution, crosses placenta and enters breast milk
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: 90-100%, minimal first-pass effect
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dose adjustment required. Contraindicated in severe renal impairment or acute renal failure due to potential for fluid retention and hyperkalemia.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in Child-Pugh class B or C hepatic impairment. Use with caution in Child-Pugh class A (mild impairment) with monitoring.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not indicated for use before menarche. For postmenarcheal adolescents, same dosing as adults: 1 tablet orally daily.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for use after menopause. No specific dose adjustment; consider thromboembolic risk and comorbidities.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events from oral contraceptive use. Risk increases with age (especially in women >35 years) and with number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Increased risk of thromboembolic disorders, including venous thromboembolism and arterial thrombosis,Risk of myocardial infarction and stroke, especially in smokers and women with hypertension or other cardiovascular risk factors,Hepatic neoplasia (benign and malignant) reported,Gallbladder disease,Carbohydrate and lipid metabolism alterations,Elevated blood pressure,Headache including migraine,Irregular bleeding and amenorrhea,Depression,Carcinoma of the breast and reproductive organs (no conclusive evidence),Decreased effectiveness with concurrent medications like rifampin, anticonvulsants
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebrovascular or coronary artery disease,Known or suspected pregnancy,Undiagnosed abnormal uterine bleeding,Known or suspected breast carcinoma,Hepatic tumors (benign or malignant) or acute liver disease,Uncontrolled hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms,Major surgery with prolonged immobilization,Smoking in women over 35 years
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No specific food restrictions. Grapefruit juice may increase estrogen levels; avoid excessive consumption. High-fat meals may slightly reduce absorption but not clinically significant.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
First trimester: Ethinyl estradiol and norethindrone are contraindicated in pregnancy due to risk of fetal harm, including cardiovascular and limb defects. Second/third trimester: Exposure may increase risk of neonatal withdrawal, jaundice, and fluid retention.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk. M/P ratio not established. May reduce milk production and quality. Use caution, especially in the early postpartum period. Avoid if alternative contraception available.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Contraindicated in pregnancy; no dose adjustment rationale. No pharmacokinetic data supporting use in pregnancy.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
BRIELLYN is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Advise patients to take at the same time daily to maintain consistent hormone levels. Missed doses increase risk of breakthrough bleeding and pregnancy. Counsel on potential decreased efficacy with certain medications (e.g., rifampin, anticonvulsants). Monitor blood pressure at baseline and follow-up due to estrogenic effects. Discontinue if migraine with aura or unexplained vision changes occur.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one pill daily at the same time, even if you do not have sex.,If you miss a pill, follow the package instructions or consult your healthcare provider.,Use a backup barrier method (e.g., condoms) for the first 7 days of starting BRIELLYN.,Report severe headaches, vision changes, leg pain, or chest pain immediately.,Do not smoke while taking BRIELLYN, especially if over 35, due to increased risk of blood clots.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRIELLYN vs ALYACEN 7/7/7, answered by our medical review team.
BRIELLYN is a Oral Contraceptive that works by Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) that inhibits gonadotropin secretion, primarily suppressing ovulation and altering cervical mucus and endometrial lining.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRIELLYN and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRIELLYN is: BRIELLYN (ethinyl estradiol / norethindrone) 1 tablet (0.035 mg ethinyl estradiol / 0.5 mg norethindrone) orally once daily at the same time each day.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRIELLYN and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRIELLYN is classified as Category C. First trimester: Ethinyl estradiol and norethindrone are contraindicated in pregnancy due to risk of fetal harm, including cardiovascular and limb defects. Second/third trimester: . ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.